Date : July 17, 2018
New Opportunity: PositiveID Corp. (OTCMKTS: PSID)
As we start to ramp things back up for what looks to be a massive run in the OTC market space during H2 2018, we walk to kick things off with a potentially gargantuan opportunity: PSID.
We’re going to delve into all of the details of this remarkable and interesting little stock below, but it’s important that we first summarize the situation and why this could be such an interesting opportunity:
The simple story for PSID is a company that has been scraping away in the scientific device technology space for several years, and is just starting to get traction on what could be some interesting levels of success.
The float is tiny – just over 9 million shares – and the chart is screaming of bounce potential as the stock’s recent washout lows hold repeatedly and volume goes through the roof. As the company’s most disruptive product line begins to get some meaningful traction, we thought it was a perfect time to take a close look at this interesting opportunity.
Company: PositiveID Corp.
Latest News: http://finance.yahoo.com/q/h?s=PSID+Headlines
Company Website: http://www.psidcorp.com
Who is PSID?
Who is PSID
PositiveID Corp (OTCMKTS:PSID) frames itself as a company that develops and sells molecular diagnostic systems for bio-threat detection and rapid medical testing.
PSID, together with its subsidiaries, develops and sells molecular diagnostic systems for bio-threat detection and rapid medical testing.
The company focuses on microfluidic systems for the automated preparation and performance of biological assays to detect biological threats at high-value locations and analyze biological samples at the point of need. It has a portfolio of intellectual property related to sample preparation and rapid medical testing applications.
The company’s M-BAND technology is a bio-aerosol monitor with integrated systems for sample collection, processing, and detection modules. M-BAND technology analyzes air samples for the detection of pathogenic bacteria, viruses, and toxins for up to 30 days.
The company’s Firefly Dx is an automated pathogen detection system for rapid diagnostics for clinical and point-of-need applications. Firefly Dx system detects and identifies common pathogens and diseases, such as E. coli, methicillin-resistant staphylococcus aureus, methicillin-susceptible staphylococcus aureus, clostridium difficile, influenza, and others.
In addition, PositiveID Corporation markets the Caregiver, a non-contact clinical thermometer that measures forehead temperature in adults, children, and infants for hospitals, physicians’ offices, medical clinics, nursing homes and other long-term care institutions, and acute care hospitals; and manufactures and sells specialty technology vehicles for mobile labs, command and communications centers, and cellular applications.
This stock is positively loaded with major potential right now.
Perhaps most importantly, the company actually recently announced the debut and U.S. market release of TIR-1, a non-contact Bluetooth-enabled thermometer that integrates seamlessly with the Masimo Root patient monitoring and connectivity platform.
This is major news and could ultimately result in new interest for the stock as things play out. The Bluetooth configuration is truly a potential game changing disruption in the space.
Joe Kiani, Founder and CEO of Masimo, said, “TIR-1 is a great example of the powerful expandability and versatility of the Root platform, and of our commitment to improving patient care through streamlined and automated workflows. This thermometer makes it easy to efficiently take the temperatures of multiple patients without having to manually record data. We’re delighted to have partnered with Thermomedics to develop an additional, easy-to-use thermometry option for Root customers.”
Most recently, the company announced that its ExcitePCR subsidiary has joined Cambridge Healthtech Institute’s meeting of internationally recognized experts in detection and biological threats, Biodetection Technologies: Biothreat and Pathogen Detection. This is yet another major success for the company as it continues to put itself on the map. Public awareness is always a massive objective for this stage, and this event will likely pay off in spades down the line.
Just before that, the company announced a new substantive interview (you should check this out) with Chairman and CEO William J. Caragol that details the Company’s private label distribution agreement, announced last month, with a global leader in non-invasive patient monitoring systems.
With all of these major themes playing together, the picture we see on the chart doesn’t make a whole heckuva lot of sense, and so that’s where we are now going to turn our attention.
With PSID, we are talking about a stock that has truly been left-for-dead by many of its more fickle shareholders over the past two months. But we are also talking about a stock the trades on a tiny float, with just over 9 million shares rattling around on the spread.
Our ears always “perk up” when we see something where the spec money has already left the game, there’s a ton of interesting things going on at the company, and we’re dealing with a small float on drastically rising average daily trading volume.
This last point actually maybe the most important of all: you see, a tiny trading float like this doesn’t necessarily come into play in terms of how the stock acts. However, when you pair a small float like this up with a major ramp in average trading volume (we have seen average volume quadruple just in recent days, and a steady rise in the statistic over the last month), you suddenly move into territory where it’s possible to see a massive squeeze hit the charts.
That’s why it’s also important to note that the 14-day RSI measure is coming off of massively extreme oversold levels, which paves the way for that squeeze even more. And, given all of the interesting and powerful themes in play for this story described above, it’s all the more reason that this stock needs to be on your radar front and center right now.
PSID (PositiveID Corporation), together with its subsidiaries, develops and sells molecular diagnostic systems for bio-threat detection and rapid medical testing.
PSID focuses on microfluidic systems for the automated preparation and performance of biological assays to detect biological threats at high-value locations and analyze biological samples at the point of need.
PSID has a portfolio of intellectual property related to sample preparation and rapid medical testing applications.
PSID’s M-BAND technology is a bio-aerosol monitor with integrated systems for sample collection, processing, and detection modules. M-BAND technology analyzes air samples for the detection of pathogenic bacteria, viruses, and toxins for up to 30 days.
- PSID has a small trading float of just 9.3M, which suggests the stock could launch higher on any additional influx of interest.
- PSID is making real money, with trailing revs already coming in at $4.6M.
- PSID just reported a huge jump in sales, along with a breakthrough in marketing its disruptive Bluetooth-enabled caregiver device.
- PSID has been stacking up catalysts in three promising lines of business as the chart starts to show a turnaround in action.
- PSID is coming off an RSI trough under 40, and is now sporting a clean bullish RSI divergence pattern.
- PSID is seeing a massive jump in average trading volume.
When it comes right down to it, PSID could well be setting up for a powerful inflection of its current lows.
The tea leaves suggest that, due to a massive jump in average trading volume over the past month of action, when paired with a tiny float of just over 9 million shares, the potential for a squeeze off of current levels in the stock is high just from a strictly mechanical standpoint.
However, when you also consider strong advances for its cutting-edge, game changing Bluetooth enabled market-leading technology – a disruptive tool with massive commercial application potential in the medical device technology space – and the jump in exposure that the company has recently seen, it almost feels as though you’re already playing with house money on this one.
Furthermore, when you throw in the fact that the speculative money has already been washed out of the stock, taking a look at it here is like standing in a basement and watching the doors open to an elevator.